Madde Kullanım Bozukluklarının Nörobiyolojik Temelleri

Authors

İ. Tayfun Uzbay
https://orcid.org/0000-0002-9784-5637

Synopsis

Substance addiction is a neuropsychiatric disorder that begins with misuse and evolves into a chronic brain disease through "reverse adaptation" or "remodeling" resulting from altered neuroplasticity. The process is closely linked to the brain's reward system, which delivers pleasure and euphoric effects. The mesolimbic and mesocortical pathways between the ventral tegmental area (VTA) and nucleus accumbens (NAc) play a key role in positive reinforcement and reward stimulation, with dopamine serving as the primary neurotransmitter. Additionally, neurochemicals such as GABA, glutamate, serotonin, noradrenaline, adenosine, endogenous opioids, nitric oxide, and agmatine contribute to the development of addiction, reinforcement, and withdrawal syndrome. The reward system consists of a limbic "reactive" component conveying pleasurable impulses and a cortical "reflective" component in the prefrontal cortex (PFC) governing decisions and self-control. Substance use disorders are not tied to a single gene but exhibit a polygenic nature shaped by environmental factors, epigenetics, and multi-gene interactions. Neuroadaptations and "terrorist neurons" resulting from chronic use impede radical treatment, creating a chronic condition marked by relapses.

References

Olds J, Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 1954;47: 419-427.

Edwards S. Reinforcement principles for addiction medicine; from recreational drug use to psychiatric disorder. Prog Brain Res 2016;223: 63-76.

Meyer PJ, King CP, Ferrario CR. Motivational processes underlying substance abuse disorder. Curr Top Behav Neurosci 2016; 27: 473-506.

Uzbay İT. Beyin nasıl bağımlı oluyor. MİSED (Türk Eczacıları Birliği Meslek İçi Sürekli Eğitim Dergisi) 2009;Aralık (21-22): 34-48.

Uzbay İT. Madde Bağımlılığı. İstanbul: İstanbul Tıp Kitabevi; 2015. p. 18-138.

Koob FG. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13: 177-184.

Wise RA, Bozart MA. A Psychomotor stimulant theory of addiction. Psychol Rev 1987;94: 469-492.

Pierce RC, Kumaresan V. The mesolimbic dopamine system: The final common pathway fort he reinforcing effect of drugs of abuse. Neurosci Biobehav Rev 2006;30: 215-238.

Uzbay IT. Nöropsikofarmakoloji – Akılcı Nöropsikiyatrik İlaç Kullanımı. İstanbul: İstanbul Tıp Kitabevi; 2019. p. 34.

Hoehn-Saric R. Neurotransmitters in anxiety. Arch Gen Psychiatry 1982;39: 735-742.

Uzbay IT, Akarsu ES, Kayaalp SO. Effects of flumazenil (Ro 15-1788) on ethanol withdrawal syndrome in rats. Arzneim Forsch-Drug Res 1995;45: 120-124.

O’Brien CP. Drug addiction and abuse. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds.) Goodman and Gilman’s The Pharmacological Basis of Therapeutics içinde New York: McGraw-Hill; 1996. p. 557-577.

Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995;152: 332-340.

Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991;251: 85-87.

Uzbay IT, Usanmaz SE, Tapanyiğit EE, et al. Dopaminergic and serotonergic alterations in the rat brain during ethanol withdrawal: association with behavioral signs. Drug Alcohol Depend 1998;53: 39-47.

Uzbay IT, Usanmaz S, Akarsu ES. Effects of chronic ethanol administration on serotonin metabolism in the various regions of the rat brain. Neurochem Res 2000;25: 257-262.

Uzbay IT. Serotonergic antidepressants and ethanol withdrawal syndrome: A review. Alcohol Alcohol 2008;43: 15-24.

Uzbay TI. Atypical antipsychotic drugs and ethanol withdrawal syndrome: A review. Alcohol Alcohol 2012;47: 33-41.

De Deurwaerdère P, Di Giovanni G. Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications. Prog Neurobiol 2017;151: 175-236.

Linnoila M, Mefford I, Nutt D, et al. NIH conference. Alcohol withdrawal and noradrenergic function. Ann Intern Med 1987;107: 875-889.

Jain N, Kemp N, Adeyemo O, et al. Anxiolytic activity of adenosine receptor activation in mice. Br J Pharmacol 1995;116: 2127-2133.

Wilson J, Little HJ. CCK(B) antagonists protect against some aspects of the ethanol withdrawal syndrome. Pharmacol Biochem Behav 1998;59: 967-973.

Uzbay IT, Oglesby MW. Nitric oxide and substance dependence. Neurosci Biobehav Rev 2001;25: 43-52.

Uzbay TI. Pharmacological importance of agmatine in brain. Neurosci Biobehav Rev 2012;36: 502-519.

Uzbay T. A new target for diagnosis and treatment of CNS disorders: Agmatinergic system. Curr Med Chem 2012;19: 5116-5121.

Yeşilyurt Ö, Uzbay IT. Agmatine potentiates the analgesic effect of morphine by an alpha-2-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 2001;25: 98-103.

Arıcıoğlu-Kartal F, Uzbay IT. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci 1997;61: 1775-1781.

Uzbay IT, Erden BF, Tapanyiğit EE, et al. Nitric oxide synthase inhibition attenuates signs of ethanol withdrawal in rats. Life Sci 1997;61: 2197-2209.

Uzbay IT, Kayir H, Goktalay G, et al. Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats. J Psychopharmacol 2010;24: 923-929.

Uzbay T, Goktalay G, Kayir H, et al. Increased plasma agmatine levels in patients with schizophrenia. J Psychiat Res 2013;47: 1054-1060.

Stahl SM. Stahl’s Essential Psychopharmacology. 3rd Edition, New York: Cambridge University Press; 2008.

Uzbay İT. Bağımlılığın nörobiyolojisi. Dilbaz N, Göğcegöz I, Noyan CO, Kazan Kızılkurt Ö (eds.) Bağımlılık Tanı ve Tedavi Temel Kitabı içinde. Ankara: Ankara Nobel Tıp Kitabevi; 2021 (Baskıda).

Carter R, Aldridge S, Page M, et al. Beyin Kitabı. Çeviren: Güneş Kayacı, İstanbul: Alfa Yayınları; 2013. p. 124-128.

Morrow JD, Flagel SB. Neuroscience of resilence and vulnerability for addiction medicine: From genes to behavior. Prog Brain Res 2016;223: 3-18.

Hurley TD, Edenberg HJ. Genes encoding enzymes involved in ethanol metabolism. Alcohol Res 2012;34: 339-44.

Bierut LJ, Stitzel JA, Wang JC, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 2008;165: 1163-1171.

Wang J-C, Kapoor M, Goate AM. The genetic of substance dependence. Annu Rev Genomics Hum Genet 2012;13: 241-261.

Hall FS, Drgonova J, Jain S, et al. Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? Pharmacol Ther 2013;140: 267-279.

Renthal W, Nestler EJ. Epigenetic mechanisms in drug addiction. Trends Mol Med 2008;14: 341-350.

Uzbay T., Öz P, Gözaydınoğlu Ş. Genoplasticity and neuropsychiatric diseases. Curr Top Pharmacol 2019;23: 69-82.

Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 2011;12: 623-637.

Nestler EJ, Lüscher C. The molecular basis of drug addiction: Linking epigenetic to synaptic and circuit mechanisms. Neuron 2019;102: 48-59.

Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Genet 2005;132B: 29-37.

Uzbay IT. Madde bağımlılığı ve dopaminerjik sistem. Türkiye Klinikleri, Dahili Tıp Bilimleri Psikiyatri (Alkol ve Madde Bağımlılığı Özel Sayısı) 2006;1(47): 65-72.

Blum K, Noble EP, Sheridan PJ, et al. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 1991;8: 409-416.

Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 2003;116: 103-125.

Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000;32(Suppl. i-iv): 1-112

Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000;126: 325-341.

Gelernter J, O’Malley S, Risch N, et al. No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. JAMA 1991;266: 1801-1807.

Edenberg HJ, Foroud T, Koller DL, et al. A family-based analysis of the association of the dopamine D2 receptor (DRD2) with alcoholism. Alcohol Clin Exp Res 1998;22: 505-512.

Rutherford HJ, Williams SK, Moy S, et al. Disruption of maternal parenting circuitry by addictive process: rewiring of reward and stress systems. Front Psychiatry 2011;2: 37.

Kovács KJ. Microglia and drug-induced plasticity in reward-related neuronal circuits. Front Mol Neurosci 2012;5: 74.

Le Moal M, Koob GF. Drug addiction: Pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol 2006;17: 377-393.

Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993;14: 69-77.

Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001;158: 2015-2021.

Published

November 4, 2021

License

License